Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Fifty-Two-Week Multicenter, Open-Label, Study Evaluating the Long-Term Safety and Tolerability of SR58611A 350 mg q12 in Patients With Major Depressive Disorder.

NCT00855530 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00855530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00855530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Fifty-Two-Week Multicenter, Open-Label, Study Evaluating the Long-Term Safety and Tolerability of SR58611A 350 mg q12 in Patients With Major Depressive Disorder.
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
July 31, 2007
Enrollment
527 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorders